In Novo Nordisk’s randomized clinical trial, semaglutide reduced the risk for major adverse cardiovascular events by 14% ...

The oral semaglutide reduced the occurrence of major adverse cardiovascular events (MACE) by 14% in patients with T2D.

A late-stage study shows that Novo Nordisk's oral semaglutide, Rybelsus, cuts the risk of MACE by 14% in T2D patients ...

Novo expects to file for a label expansion for Rybelsus in the United States and the European Union around the turn of the ...

Novo Nordisk faces competition from Eli Lilly in new therapeutic areas. Read why I rate NONOF stock as a hold.

According to new data from the SOUL trial Oral semaglutide reduced MACE by 14% in Type 2 Diabetes patients. Novo Nordisk will ...

Bernstein said Novo Nordisk (NVO) study results that showed certain Rybelsus users had a 14% risk reduction for major ...

The global Oral proteins and peptides market is projected to reach USD 7.38 billion in 2024 will increase to USD 20.36 billion by 2029, with ...

In a phase III trial of adults with type 2 diabetes with heart disease and/or chronic kidney disease, oral semaglutide ...

DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing weight loss groupsAccelerated rates of weight loss were experienced during the final 4 weeks of the study in all ...

In Washington state, four agricultural workers tested presumptively positive for avian influenza after contact with infected ...